60 Degrees Pharmaceuticals, Inc.SXTP
Price (close)
$1.15
Market cap
$3.1M
P/E
—
Revenue (TTM)
$1.1M
Net income
-$8.1M
Dividend yield
—
1-year total return
-79.3%
Net margin
-729.9%
Revenue growth
73.2%
Debt / equity
0.06x
What 60 Degrees Pharmaceuticals, Inc. does.
No business description on file yet.
Revenue and profit, by fiscal year.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | — | $223,208 | $253,573 | $607,574 | $1.0M |
| Net income | — | -$6.2M | -$3.8M | -$7.9M | -$7.4M |
| Free cash flow | — | — | -$4.6M | -$5.8M | -$7.0M |
More on SXTP.
- 60 Degrees Pharmaceuticals, Inc. summary
- 60 Degrees Pharmaceuticals, Inc. financial statements
- 60 Degrees Pharmaceuticals, Inc. key metrics
- 60 Degrees Pharmaceuticals, Inc. health scores and style box
- 60 Degrees Pharmaceuticals, Inc. earnings
- 60 Degrees Pharmaceuticals, Inc. dividends
- 60 Degrees Pharmaceuticals, Inc. valuation
- 60 Degrees Pharmaceuticals, Inc. ownership and insiders
- 60 Degrees Pharmaceuticals, Inc. peers
Figures from 60 Degrees Pharmaceuticals, Inc.'s filings with the U.S. SEC, standardised automatically; prices are end-of-day closes. Not financial advice.